Research programme: B-cell malignancy therapies - Zalicus

Drug Profile

Research programme: B-cell malignancy therapies - Zalicus

Alternative Names: CRx-501

Latest Information Update: 01 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CombinatoRx
  • Developer EPIRUS Biopharmaceuticals
  • Class
  • Mechanism of Action Adenosine A2A receptor agonists; Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued B cell lymphoma; Multiple myeloma

Most Recent Events

  • 25 Jul 2016 EPIRUS Biopharmaceuticals files for Chapter 7 bankruptcy (Epirus Biopharmaceuticals 8-K, July 2016)
  • 17 Jul 2014 No development reported - Preclinical for B-cell lymphoma in USA (Parenteral)
  • 17 Jul 2014 No development reported - Preclinical for Multiple myeloma in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top